GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envoy Medical Inc (NAS:COCHW) » Definitions » Operating Margin %

Envoy Medical (Envoy Medical) Operating Margin % : -8,301.69% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Envoy Medical Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Envoy Medical's Operating Income for the three months ended in Mar. 2024 was $-4.90 Mil. Envoy Medical's Revenue for the three months ended in Mar. 2024 was $0.06 Mil. Therefore, Envoy Medical's Operating Margin % for the quarter that ended in Mar. 2024 was -8,301.69%.

The historical rank and industry rank for Envoy Medical's Operating Margin % or its related term are showing as below:

COCHW' s Operating Margin % Range Over the Past 10 Years
Min: -6564.98   Med: -3673.42   Max: -2216.45
Current: -6564.98


COCHW's Operating Margin % is ranked worse than
97.2% of 820 companies
in the Medical Devices & Instruments industry
Industry Median: 0.94 vs COCHW: -6564.98

Envoy Medical's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Envoy Medical's Operating Income for the three months ended in Mar. 2024 was $-4.90 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.50 Mil.


Envoy Medical Operating Margin % Historical Data

The historical data trend for Envoy Medical's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envoy Medical Operating Margin % Chart

Envoy Medical Annual Data
Trend Dec21 Dec22 Dec23
Operating Margin %
-2,216.45 -3,673.42 -5,813.61

Envoy Medical Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only -4,834.62 -7,111.11 -4,231.25 -7,089.47 -8,301.69

Competitive Comparison of Envoy Medical's Operating Margin %

For the Medical Devices subindustry, Envoy Medical's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Envoy Medical's Operating Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Envoy Medical's Operating Margin % falls into.



Envoy Medical Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Envoy Medical's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-18.371 / 0.316
=-5,813.61 %

Envoy Medical's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-4.898 / 0.059
=-8,301.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Envoy Medical  (NAS:COCHW) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Envoy Medical Operating Margin % Related Terms

Thank you for viewing the detailed overview of Envoy Medical's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Envoy Medical (Envoy Medical) Business Description

Traded in Other Exchanges
Address
4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is focused on designing, developing, and marketing fully implantable medical devices that improve hearing. The Company's first commercial product, the Esteem PMA application, is a fully implantable hearing device. The Esteem PMA was cleared in 2010 by the United States Food and Drug Administration. The Company intends to continue to pursue the development of a cochlear implant.